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OBJECTIVES: To estimate the effect of an evidence-based
depression care management (DCM) intervention on the
initiation and appropriate use of antidepressant in primary
care patients with late-life depression.
DESIGN: Secondary analysis of data from a randomized
trial.
SETTING: Community, primary care.
PARTICIPANTS: Randomly selected individuals aged 60
and older with routine appointments at 20 primary care
clinics randomized to provide a systematic DCM interven-
tion or care as usual.
METHODS: Rates of antidepressant use and dose ade-
quacy of patients in the two study arms were compared at
each patient assessment (baseline, 4, 8, and 12 months). For
patients without any antidepressant treatment at baseline, a
longitudinal analysis was conducted using multilevel logis-
tic models to compare the rate of antidepressant treatment
initiation, dose adequacy when initiation was first recorded,
and continued therapy for at least 4 months after initiation
between study arms. All analyses were conducted for the
entire sample and then repeated for the subsample with
major or clinically significant minor depression at baseline.
RESULTS: Rates of antidepressant use and dose adequacy
increased over the first year in patients assigned to the
DCM intervention, whereas the same rates held constant in
usual care patients. In longitudinal analyses, the DCM in-
tervention had a significant effect on initiation of antide-
pressant treatment (adjusted odds ratio (OR) 5 5.63,
Po.001) and continuation of antidepressant medication
for at least 4 months (OR 5 6.57, P 5.04) for patients who
were depressed at baseline.
CONCLUSIONS: Evidence-based DCM models are highly
effective at improving antidepressant treatment in older
primary care patients. J Am Geriatr Soc 57:895–900, 2009.
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Depression in older adults is a common and debilitatingdisease. It is estimated to affect approximately 3% of
community-dwelling older people and as many as 10% of
older primary care patients.1–3 It is associated with signifi-
cant emotional morbidity, serious functional decline,4,5 and
risk of death from suicide and other medical illnesses.6 De-
spite the existence of effective treatment for depression,
late-life depression remains seriously underdetected and
under- or mistreated in primary care.7–9
Antidepressant medications are the most commonly
used treatments for depression in primary care. The keys to
effective antidepressant therapy, once initiated, are close
follow-up and regimen adjustment based on side effects,
drug interactions, and treatment response during the initial
8 to 10 weeks of treatment10 and longer-term continuation
after remission to prevent recurrence of depression.11,12 In
reality, suboptimal dosages and failure to complete an ad-
equate course of therapy often characterize antidepressant
treatment.13,14 In older patients with depression, declining
physical health and cognitive abilities make effective anti-
depressant treatment an even more daunting task.
The Prevention of Suicide in Primary Care Elderly:
Collaborative Trial (PROSPECT) developed a systematic
depression care management (DCM) program targeting
late-life depression in primary care.15 The program featured
practice-based depression care managers (e.g., nurses or
social workers) who collaborated with physicians by help-
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ing them recognize depression (and therefore initiate treat-
ment) in older adults, offered guideline-based recommen-
dations, closely monitored patient status, and provided
follow-up care. This intervention proved highly effective,
compared with care as usual, in reducing suicidal ideation15
and mortality16 in older patients with depression, as well as
in reducing depressive symptoms in older patients with
major depression.
This study assessed the effect of the PROSPECT DCM
program on effective antidepressant treatment in older pa-
tients with depression, a major intended process outcome of
the intervention, to help elucidate how the intervention
achieved better depression outcomes. Longitudinal data
from four patient assessments conducted in the first year of
the PROSPECT study were analyzed to estimate the effect
of DCM on the initiation and appropriate use of antide-
pressants in primary care patients with late-life depression.
Because pharmacotherapy is the predominant modality of
treatment for depression in primary care settings17 and be-
cause psychotherapy use in the PROSPECT data was not
clinically well defined, given that data available for all pa-
tients were based on patient self-report, it was decided to
focus on engagement in antidepressant treatment as the
primary outcome of interest in this study.
METHODS
Design of the PROSPECT Study
The PROSPECT study recruited 20 primary care practices
located in greater New York City, Philadelphia, and Pitts-
burgh and randomized them to intervention or to care as
usual. The intervention had two major components: phy-
sician education regarding treating geriatric depression and
treatment management operationalized by a care manager.
The clinical algorithms of the intervention recommended a
selective serotonin reuptake inhibitor (SSRI) as first-line
depression treatment, but physicians could refer patients for
interpersonal psychotherapy provided by the care manager
if patients refused or failed to respond to antidepressants.
The intervention protocol was designed to target the acute,
continuation, and maintenance phases of treatment. Previ-
ous publications15,18 have described PROSPECT study de-
sign, recruitment, and intervention procedures in detail.
Study Sample
The PROSPECT study enrolled randomly selected individ-
uals aged 60 and older with routine primary care appoint-
ments at the study sites. Of the 1,226 patients who
completed the baseline interview, 599 were identified as
having major depression or clinically significant minor de-
pression based on the Structured Clinical Interview for Axis
I Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition (SCID),19 with criteria for minor depression
modified by requiring four depressive symptoms of at least
4 weeks and a Hamilton Depression Rating Scale (HDRS)
score of 10 or higher. Several previous reports evaluated
outcomes for this subsample of patients,15,16,20 because
these were the patients clinically eligible for the intervention
at baseline. Although the remaining 627 patients did not
have a clinical diagnosis based on the SCID, 72 had an
HDRS score of 10 or higher at baseline (indicating transient
depressive symptoms). Analyses of the entire cohort
(N 5 1,226) were conducted, as well as of the subsample
of patients with depression at baseline (n 5 599).
Measures
Antidepressant Medication
The Composite Antidepressant (CAD) Score21 was used to
construct several measures of antidepressant use. Patients
were asked to bring all medications that they were currently
taking to in-person interviews at baseline and 12 months.
At the 4- and 8-month telephone interviews, they were
asked to bring medications to the phone. The interviewers
recorded the name, dosage, and prescribed frequency of
administration for each medication. Based on information
provided on antidepressants, a CAD score was constructed
to reflect the presence and dose adequacy of antidepressant
therapy for each patient at each assessment time point. The
CAD score took integer values and ranged from 0 to 4, with
0 indicating no antidepressant, 1 to 2 indicating antide-
pressant treatment with an inadequate dose, and 3 to 4
indicating antidepressant treatment with an adequate dose.
For cross-sectional analyses using data from each of the
4-month interviews, dichotomous measures of any antide-
pressant use (CAD score 40 vs 0) and antidepressant treat-
ment with adequate dosage (CAD score 3 vs o3) were
constructed.
For longitudinal analyses, patients who were not taking
an antidepressant at baseline were focused on, and new
initiation of antidepressant within 4 or 8 months after
baseline, adequate dosage at the time new initiation was
recorded (at the 4- or 8-month assessment), and continued
treatment for at least 4 months after initiation were mea-
sured. New initiation was determined if the patient subse-
quently had some antidepressant use at 4 months (CAD
score 40), regardless of their treatment status at 8 or 12
months, or if they had no antidepressant use at 4 months
but had use at 8 months, regardless of their treatment status
at 12 months. Adequacy of dosage was defined as a CAD
score of 3 or greater at 4 months if newly initiated in the
interim before the 4-month interview or at 8 months if
newly initiated in the interim between the 4- and 8-month
interviews. Continued treatment was identified by deter-
mining whether the patient, once initiated on an antide-
pressant, was still taking an antidepressant at the next
interview (8 or 12 months). Because these measures were
based on information collected at discrete assessment points
(rather than continuously over time), they did not capture
dose changes or interruptions in pharmacotherapy in the
intervening time between assessments.
Baseline Depression Severity and Comorbidities
Depression severity at baseline was assessed using the 24-
item HDRS,22 which ranges from 0 to 40, with higher
scores indicating greater severity.
A Charlson Comorbidity Index23 was constructed
based on patient self-reports at baseline about major health
events and chronic conditions.
Analysis
Two sets of analyses were performed: descriptive analyses
of each cross-sectional and longitudinal outcome measure
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and a model-based analysis of longitudinal outcomes. In
the descriptive analyses, means of each outcome were
calculated, and differences were tested for across the two
study arms. Statistical inferences were based on a Pearson
chi-square test of independence with a correction of
degrees of freedom to account for the design effect as a
result of patients being clustered within primary care prac-
tices.24,25 For each longitudinal outcome in patients not
taking antidepressants at baseline (i.e., initiation of anti-
depressant by 4 or 8 months, adequate dosage at the
time initiation was first recorded, and continued treat-
ment for at least 4 months), a multilevel logistic model
was estimated with a practice-level random effect to
account for correlated outcomes of patients within the
same practice. Patient sex, baseline age, marital status,
living status (with someone vs alone), baseline HDRS
score, and Charlson Comorbidity Index were controlled
for. Adjusted odds ratios (ORs) associated with the inter-
vention status (vs usual care) are reported for each
outcome.
Additional analyses were conducted to assess the extent
to which the effect of the DCM intervention on depression
outcomes operated through better pharmacotherapy, psy-
chotherapy, or both. Three outcomes were considered: re-
sponse to treatment indicated by a 50% reduction in
the HDRS score from baseline, remission defined as having
a HDRS score less than 7, and remission defined as having a
HDRS score less than 10.15 Focusing on patients with major
or clinically significant minor depression but no antide-
pressant at baseline, a model of each of the depression out-
comes at each assessment (4, 8, and 12 months) was first
estimated as a function of the DCM intervention, control-
ling for baseline HDRS, suicidal ideation, and major versus
minor depression to assess the intention-to-treat interven-
tion effect. Dichotomous indicators of any antidepressant
use and dose adequacy at the time of the assessment and any
psychotherapy use during the 4 months before the assess-
ment were then added to examine the mediating effects of
depression treatment.
RESULTS
Patient baseline demographic and depression-related clin-
ical characteristics are summarized in Table 1 for all pa-
tients and for the subsample with major or clinically
significant minor depression at baseline. A majority of study
patients were female, and more than one-third were aged 75
and older. Although patients in the intervention arm were
less likely to be racial or ethnic minorities, more likely to
have a clinical depressive diagnosis at baseline, and had
higher HDRS and CES-D scores, none of these differences
was statistically significant. Other than having greater se-
verity and more symptoms of depression, patients with a
diagnosis of depression at baseline were younger and less
likely to be living with someone else than the entire sample.
The two study arms were balanced in terms of patient
characteristics in the subsample with depression.
Table 2 presents cross-sectional measures of antide-
pressant use. Of the entire sample, 31% of the intervention
patients were taking an antidepressant at baseline, com-
pared with 29% of the usual care patients. Although the
treatment rate in usual care patients remained relatively
constant during the next 12 months, the rate in the inter-
vention patients continued to rise; by the end of the first
year, 46% were taking antidepressant medication (Po.05
for comparisons at 8 and 12 months). A similar pattern held
for adequacy of antidepressant dosage; the proportion of
patients who received antidepressant treatment with ade-
quate dosage increased from 23% at baseline to 36% at 12
months in intervention patients, whereas the same measure
stayed almost constant in the usual care patients through-
out the first year. Again, differences according to interven-
tion status achieved statistical significance with Po.05
starting from 8 months. Antidepressant use in patients with
Table 1. Baseline Patient Characteristics of Study Samples According to Intervention Status
Characteristic














Female 68.1 71.6 .29 69.1 74.6 .20
Aged 75 35.1 34.8 .95 31.9 29.7 .63
Racial or ethnic minority 28.7 36.8 .62 29.1 36.8 .63
Married 39.5 37.7 .82 36.4 37.7 .89
Living with someone else 56.3 56.1 .96 43.5 43.7 .97
Clinical
Diagnosis of depression, % 52.5 45.2 .16 100.0 100.0 F
Mean HDRS score 12.0 10.8 .25 18.4 17.4 .16
Mean Center for Epidemiologic Studies Depression Scale
score
21.0 20.4 .62 27.2 27.2 .99
Charlson Comorbidity Index 2.7 2.6 .64 3.1 2.9 .53
Major or clinically significant minor depressive disorder based on the Structured Clinical Interview for Axis I Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition, with criteria for minor depression modified by requiring four depressive symptoms of at least 4 weeks and a Hamilton Depression
Rating Scale (HDRS) score of 10 or higher.
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clinical depression, for whom antidepressant treatment is
most clearly indicated, presented a similar, if not stronger,
pattern; the rate of treatment with adequate dose increased
more than 1.6 times in intervention patients, from 33.2% at
baseline to 55.0% at 12 months, whereas the rate of treat-
ment increased slightly in the usual care arm. The inter-arm
differences achieved statistical significance (Po.05) starting
with the 4-month interview.
Results of descriptive and model-based analyses of
longitudinal outcomes for the group with no antidepressant
treatment at baseline are reported in Table 3. In the de-
scriptive analysis, intervention patients were more than
twice as likely to have initiated antidepressant by 8 months
as usual care patients (P 5.003 for all patients; P 5.001 for
patients with depressive diagnosis). Of those with newly
initiated antidepressant use, the rate of adequate dosage
when antidepressant pharmacotherapy was subsequently
first recorded did not differ significantly between the two
study arms, although a substantially higher proportion of
intervention than usual care patients continued the medi-
cation for at least 4 months once initiated (Po.05 in both
analysis samples).
Based on results of the covariate-adjusted analysis, the
DCM intervention was associated with ORs of 2.77 in the
entire sample and 5.63 in the sample with clinical depres-
sion for initiation of antidepressant treatment (Po.001 in
both cases). For adequate dosage at the time initiation was
recorded, the adjusted analysis yielded ORs of 3.11 for the
entire sample and 0.90 for the subsample with depression,
neither of which was statistically significant. For the out-
come of continued antidepressant use for at least 4 months
after initiation, the adjusted analysis yielded ORs of 10.46
(P 5.009) for the entire sample and 6.57 (P 5.04) for the
subsample with depression.
Patient characteristics controlled for in the adjusted
analysis did not predict medication outcomes, except that
patients with depression aged 75 and older were much more
likely than those aged 60 to 74 to have initiated antide-
pressant treatment by 8 months (OR 5 2.37, P 5.03).
In the mediating analysis, the intention-to-treat effect
of the intervention was found to be close to statistical sig-
nificance only at 4 months. In these models, ORs associated
with the DCM intervention were 1.88 (P 5.06) for treat-
ment response, 1.67 (P 5.09) for remission with a HDRS
score less than 7, and 1.93 (P 5.06) for remission with a
HDRS score less than 10. When treatment indicators for
antidepressant initiation and dose adequacy recorded at 4
months and any psychotherapy use in the first 4 months








Baseline 31.1 28.6 .57
4 months 38.5 27.8 .09
8 months 43.7 27.5 .02
12 months 45.6 29.6 .03
Antidepressant treatment with adequate dose
Baseline 23.1 18.8 .35
4 months 30.3 19.4 .09
8 months 34.1 20.5 .03
12 months 35.7 20.1 .03
Patients with clinical depression
Any antidepressant use
Baseline 41.7 40.2 .81
4 months 56.5 38.9 .02
8 months 64.5 42.6 .006
12 months 69.1 44.0 .007
Antidepressant treatment with adequate dose
Baseline 33.2 27.5 .39
4 months 46.9 28.1 .04
8 months 53.2 34.2 .02
12 months 55.0 33.3 .03





P-Value Odds Ratio P-Value%
All patients
Initiated antidepressant by 4 or 8 months 26.4 12.4 .003 2.77 .00
Adequate dosage when initiation was recorded 69.2 51.5 .17 3.11 .15
Continued antidepressant for at least 4 months 81.8 39.1 .01 10.46 .009
Patients with clinical depression at baseline
Initiated antidepressant by 4 or 8 months 51.9 19.4 .001 5.63 .00
Adequate dosage when initiation was recorded 66.7 68.4 .89 0.90 .76
Continued antidepressant for at least 4 months 83.0 50.0 .04 6.57 .04
Adjusted for patient sex, baseline age, marital status, living status (with someone vs alone), baseline Hamilton Depression Rating Scale score and Charlson
Comorbidity Index.
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were added, the ORs were invariably reduced in magnitude
and lost statistical significance (1.06, P 5.90; 1.36, P 5.49;
and 1.50, P 5.37, respectively), suggesting that at least part
of the intervention effect was mediated through treatment,
but it was not possible to statistically determine which di-
mension of pharmacotherapy (initiation vs dose adequacy)
had a stronger effect, because confidence intervals of the
two largely overlapped.
DISCUSSION
Collaborative depression care models developed in the past
decade have proven highly effective in improving depres-
sion treatment outcomes for older patients in primary care.
This study used data from the PROSPECT study to perform
an in-depth examination of one intended process outcome
of the intervention: use of antidepressant medication in ac-
cordance with clinical guidelines.26,27 It found that receiv-
ing the DCM intervention was associated with a
substantially greater likelihood of receiving antidepressant
medication and with adequate medication dose at 8 and 12
months into the intervention. It also found that the inter-
vention had a statistically and clinically significant effect on
whether older patients who were not receiving antidepres-
sant pharmacotherapy subsequently initiated antidepres-
sant treatment within 8 months. Furthermore, in those who
newly initiated medication, the DCM intervention was as-
sociated with an OR of at least 6 for continued medication
for at least 4 months.
A statistically significant association was not found be-
tween DCM and dose adequacy when newly initiated an-
tidepressant was first recorded. The intervention may not
have had an effect on adequate dosage at treatment initi-
ation, because up-titration in the early stage of pharmaco-
therapy is an essential element of effective antidepressant
treatment. Hence, dose adequacy shortly after a patient
newly initiates pharmacotherapy may be an overly stringent
benchmark for interventions that nonetheless effectively
engage patients in evidence-based depression treatment.
Antidepressant treatment, the outcome of interest in
the study, was not the primary outcome of the PROSPECT
study. Because the measures in the current study were based
on data collected at discrete assessment points, the outcome
of receiving antidepressant therapy at least 4 months after
treatment initiation may not accurately represent continu-
ous antidepressant treatment during that time period, but
the randomized design of the PROSPECT study makes it
likely that any systematic bias in the measure would be
balanced across the two arms. The PROSPECT study did
not collect data on medication side effects or drug interac-
tions. It was therefore not possible to examine the reasons
underlying antidepressant use with inadequate dose or pre-
mature discontinuation.
Although it was explicitly decided to focus on antide-
pressant medication as a process outcome, psychotherapy
remains an alternative or complementary treatment with
known efficacy. Of patients with depression who were not
treated with antidepressants at baseline, 50% reported
some kind of psychotherapy at the 4- or 8-month assess-
ment. By offering free interpersonal psychotherapy con-
ducted by the care managers, the PROSPECT intervention
greatly facilitated access to psychotherapy.15 By 8 months,
in patients with depression with no antidepressants at base-
line, 86% of patients in the intervention arm reported some
kind of psychotherapy, compared with 11% of those in the
usual care arm. The mediating analysis, which controlled
for psychotherapy use in addition to medication, provided
evidence that psychotherapy accounted for some of the in-
tervention effect at 4 months, although ORs between the
psychotherapy indicator and the outcomes did not achieve
statistical significance. By not considering use of psycho-
therapy in the analysis, it is likely that findings reflect
more-conservative estimates of the intervention effect on
antidepressant treatment engagement and adequacy than if
the intervention had not also lowered the cost and improved
the accessibility of psychotherapy.
In summary, one of the mechanisms by which DCM is
intended to achieve improved depression treatment for
older primary care patients was investigated: by achieving
guideline-concordant, effective antidepressant treatment.
Given that antidepressant medication is first-line treatment
for depression in primary care settings, it is likely that DCM
models that help achieve effective pharmacotherapy will
provide the greatest benefit. This is especially true for older
primary care patients, for whom underdetection and un-
dertreatment of depression poses a greater challenge, be-
cause depression may be more seriously stigmatized,28
considered a normal part of aging,29 or considered to be an
incidental epiphenomenon of other chronic conditions
rather than a serious condition in need of treatment.
The findings of the current study provide evidence that
implementing collaborative depression care management
models will help primary care practices meet nationally
recognized ‘‘best practice’’ guidelines for antidepressant
management such as those in the Healthcare Effectiveness
Data and Information Set30 and, in turn, improve outcomes
for their older patients with depression, although imple-
menting evidence-based DCM in real-world settings re-
quires overcoming a wide array of barriers.31,32 The most
pressing issues are the need to reorient and restructure pri-
mary care practices from a focus on acute care to chronic
condition management and aligning payment and financing
systems toward providing sufficient incentives for the de-
livery of evidence-based depression care. Efforts to reform
the delivery and payment systems for primary care in gen-
eral include initiatives surrounding the ‘‘Medical Home’’
concept.33,34 In the arena of DCM, one ongoing initiative is
Depression Improvement Across Minnesota, Offering a
New Direction, which offers a bundled payment negotiated
between health plans and medical groups that covers key
components of DCM activities.35 Finally, the Veterans
Health Administration is making major financial and sys-
tems changes to integrate DCM and collocated collabora-
tive mental health professionals into primary care clinics.36
Lessons learned from these and other implementation
efforts around the country will facilitate translation of ev-
idence-based DCM into primary care practice.
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